Warp Therapeutics is a biopharmaceutical company developing conditionally activated immunotherapies to treat cancer and immune-mediated diseases. The company's PREDATOR platform engineers molecules that selectively stimulate immune responses within the tumor microenvironment to overcome limitations of conventional immunotherapies; its lead programs are INDUKINE molecules (systemically delivered, conditionally activated cytokines including IL-2, IL-12, IL-21, and IL-18 variants) and INDUCER T cell engagers (bispecific antibodies). The company generates value by developing pipeline candidates for immunotherapy-resistant cancers and partnering programs (including a licensed interferon-alpha molecule with Jazz Pharmaceuticals), and plans to commercialize successful candidates through internal U.S. sales infrastructure and external partnerships.